VABYSMO

This brand name is authorized in Austria, Canada, Ecuador, France, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Romania, United Kingdom, United States

Active ingredients

The drug VABYSMO contains one active pharmaceutical ingredient (API):

1 Faricimab UNII QC4F7FKK7I - FARICIMAB

Faricimab is a humanised bispecific immunoglobulin G1 (IgG1) antibody that acts through inhibition of two distinct pathways by neutralisation of both angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A). By dual inhibition of Ang-2 and VEGF-A, faricimab reduces vascular permeability and inflammation, inhibits pathological angiogenesis and restores vascular stability. Read about Faricimab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VABYSMO Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01LA09		S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents
Discover more medicines within S01LA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02527618
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 238-MBE-1122
Country: FR	Base de données publique des médicaments	Identifier(s): 61150655
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9261
Country: IT	Agenzia del Farmaco	Identifier(s): 050231012
Country: JP	医薬品医療機器総合機構	Identifier(s): 1319408A1020
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1095545
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69155001
Country: US	FDA, National Drug Code	Identifier(s): 50242-096